21_01_BioprocessLive_SiteHeader


Welcome to Bioprocess Online Live – An interactive forum to discuss some of the most important technologies and trends impacting the biotherapeutic space.

Throughout the year, our Chief Editor, Matthew Pillar, sits down with industry experts to discuss how biopharmaceutical companies are tackling the biggest bioprocess challenges they face in the development and manufacturing of biologic therapies. These discussions often include Q&A sessions with attendees, and each Bioprocess Online Live session is archived and accessible at any time by registered site users.

UPSTREAM PROCESS INTENSIFICATION: REAL-WORLD RESULTS

  • Upstream Process Intensification: Real-World Results

    Sonnet BioTherapeutics Chief Technology Officer Susan Dexter, single-use and process intensification pioneer Parrish Galliher, and Bioprocess Online Chief Editor Matt Pillar joined at the last Bioprocess Online Live for an in-depth discussion on upstream process intensification in practice.

GENE & RNA THERAPIES: REGULATORY REQUIREMENTS TAKE SHAPE

  • Gene & RNA Therapies: Regulatory Requirements Take Shape

    Unprecedented progress in advanced therapy medicinal product development platforms leveraging AAV, mRNA, and oligonucleotide technologies are testing the mettle of biopharmas and regulatory bodies alike. Check out our On-Demand presentation of BioProcess Online Live - Gene & RNA Therapies: Regulatory Requirements Take Shape. Learn how to form up your own regulatory strategy, align your data with the most current FDA guidance, and develop a mutually-beneficial relationship with regulators in this interactive discussion with executives on the front lines of emerging ATMP regulatory requirements.

VACCINE MANUFACTURING & REGULATORY ADVANCES: RIDING COVID'S COATTAILS

  • Vaccine Manufacturing & Regulatory Advances: Riding COVID's Coattails

    Accelerated by the COVID-19 pandemic, nucleic acid, viral vector-based, inactivated, and other vaccine tech targeting a host of disease states are experiencing a rapid resurgence among biopharmas large and small. Learn how next-generation vaccine manufacturers are changing the egg yolk manufacturing paradigm and seizing an unprecedented regulatory momentum.

TACKLING THE CELL & GENE MANUFACTURING TALENT CRUNCH

  • Tackling The Cell & Gene Manufacturing Talent Crunch

    Join Project Farma and Precision ADVANCE leaders Anshul Mangal and John Khoury for a discussion with BioProcess Online Chief Editor Matt Pillar to address solutions to the biotherapeutic and cell and gene therapy process and manufacturing talent gap.

BIOPHARMA'S TOP TRENDS 2020 - PROGRESS, ACCELERATED - LOOKING TOWARD 2021

mattpillar-aboutus

Matthew Pillar

Matthew Pillar is chief editor at BioProcess Online. He's spent the past 20 years covering tech-centric industries as they’ve navigated AI, machine learning, IoT, and other emerging technologies. His chief and executive editorial experience includes tenures with Software Executive, Channel Executive, Business Solutions and ISR magazines, where he routinely interviewed international technology builders and influencers. Pillar has spoken on emerging technologies and their implications at major events for leading tech vendors including NetSuite, Oracle, SAP, and others.

Connect with Pillar on LinkedIn at linkedin.com/in/matthewpillar/